Benzinga | Jun 16, 2021 04:47PM EDT

CureVac Says COVID-19 Vaccine Demonstrated An Interim Vaccine Efficacy Of 47% Against COVID-19 Disease Of Any Severity And Did Not Meet Prespecified Statistical Success Criteria

https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/